Arrowpoint Investment Partners Singapore Pte. Ltd. Takes Position in Insmed, Inc. $INSM

Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in Insmed, Inc. (NASDAQ:INSM) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 11,556 shares of the biopharmaceutical company’s stock, valued at approximately $2,011,000. Insmed comprises approximately 0.3% of Arrowpoint Investment Partners Singapore Pte. Ltd.’s holdings, making the stock its 28th biggest position.

Other large investors have also modified their holdings of the company. CIBC Private Wealth Group LLC grew its stake in Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 53 shares during the last quarter. CoreCap Advisors LLC acquired a new position in Insmed during the 4th quarter worth $27,000. SBI Securities Co. Ltd. lifted its position in Insmed by 404.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 166 shares during the last quarter. GraniteShares Advisors LLC bought a new stake in Insmed during the fourth quarter valued at about $30,000. Finally, RiverPark Advisors LLC bought a new stake in Insmed during the third quarter valued at about $38,000.

Wall Street Analyst Weigh In

INSM has been the topic of several research analyst reports. Royal Bank Of Canada lowered their price target on Insmed from $220.00 to $205.00 and set an “outperform” rating on the stock in a research report on Friday, May 8th. Raymond James Financial assumed coverage on Insmed in a research note on Friday, April 10th. They set an “outperform” rating and a $200.00 target price for the company. Wells Fargo & Company lowered their target price on Insmed from $177.00 to $160.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. HC Wainwright reaffirmed a “buy” rating on shares of Insmed in a research report on Friday, May 8th. Finally, Bank of America upped their price target on Insmed from $211.00 to $213.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Insmed currently has an average rating of “Moderate Buy” and a consensus target price of $210.95.

Insider Activity

In other Insmed news, insider Michael Alexander Smith sold 6,149 shares of Insmed stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $108.47, for a total transaction of $666,982.03. Following the sale, the insider owned 41,613 shares in the company, valued at $4,513,762.11. The trade was a 12.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO William Lewis sold 10,699 shares of the business’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $143.97, for a total transaction of $1,540,335.03. Following the completion of the sale, the chief executive officer directly owned 301,185 shares in the company, valued at $43,361,604.45. This trade represents a 3.43% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 145,944 shares of company stock worth $22,951,391. Company insiders own 2.10% of the company’s stock.

Insmed Stock Up 1.0%

NASDAQ INSM opened at $104.92 on Friday. Insmed, Inc. has a twelve month low of $70.57 and a twelve month high of $212.75. The stock has a market cap of $22.74 billion, a PE ratio of -18.25 and a beta of 0.79. The firm has a 50-day simple moving average of $131.53 and a 200 day simple moving average of $155.38. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The firm had revenue of $305.96 million during the quarter, compared to analysts’ expectations of $300.81 million. During the same quarter in the prior year, the firm posted ($1.42) EPS. The company’s revenue for the quarter was up 229.7% on a year-over-year basis. On average, research analysts forecast that Insmed, Inc. will post -2.56 EPS for the current year.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.